Evidence for safety and efficacy of risedronate in men with osteoporosis over 4years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study

Bone

Volumn 51, Issue 3, 2012, Pages 383-388

  Boonen, Steven ^a   Lorenc, Roman S ^b   Wenderoth, Dietrich ^c   Stoner, Karen J ^d   Eusebio, Rachelle ^e   Orwoll, Eric S ^f  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^c Warner Chilcott Deutschland GmbH   (Germany)

^d Warner Chilcott UK Ltd   (United Kingdom)

^e PROCTER AND GAMBLE COMPANY   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Bisphosphonates; Bone mineral density; Bone turnover markers; Male osteoporosis; Risedronate

Indexed keywords

CALCIUM; PLACEBO; RISEDRONIC ACID; VITAMIN D;

AGED; ARTHRALGIA; ARTICLE; BACKACHE; BONE DENSITY; BONE TURNOVER; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL TOXICITY; HEADACHE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LABORATORY TEST; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PHYSICAL EXAMINATION; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; VERTEBRA FRACTURE; VITAL SIGN;

BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DEMOGRAPHY; DOUBLE-BLIND METHOD; ETIDRONIC ACID; FEMALE; HUMANS; LEAST-SQUARES ANALYSIS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOPOROSIS; PLACEBOS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84863820744     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.06.016     Document Type: Article

References (7)

1. Harris S.T., Watts N.B., Genant H.K., McKeever C.D., Hangartner T., Keller M., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999, 282:1344-1352.
2. Reginster J., Minne H.W., Sorensen O.H., Hooper M., Roux C., Brandi M.L., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000, 11:83-91.
3. Brown J.P., Kendler D.L., McClung M.R., Emkey R.D., Adachi J.D., Bolognese M.A., et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002, 71:103-111.
4. Harris S.T., Watts N.B., Li Z., Chines A.A., Hanley D.A., Brown J.P. Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. Curr Med Res Opin 2004, 20:757-764.
5. Boonen S., Orwoll E., Wenderoth D., Stoner K.J., Eusebio R., Delmas P.D. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res 2009, 24:719-725.
6. Eastell R., Barton I., Hannon R.A., Chines A., Garnero P., Delmas P.D. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003, 18:1051-1056.
7. Genant H.K., Wu C.Y., Van Kuijk C., Nevitt M.C. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993, 8:1137-1148.